4 completed. 4 Phase 1, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Completed 4 |
| Phase 2 | 2 | Completed 2 |
Follow CAN04: new trials by email Literature Review of CAN04 trials Research Report on CAN04
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Nadunolimab in Combination With Gemcitabine Plus Carboplatin in Patients With Advanced Triple Negative Breast Cancer. Carboplatin, Gemcitabine, Nadunolimab - Triple Negative Breast Cancer | Phase 1 / Phase 2 | Completed | Cantargia AB | 117 | 2022-01-11 | 2026-05-27 |
| A Study of the Safety and Tolerance of CAN04 in Combination With FOLFIRINOX in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma CAN04, FOLFIRINOX - Metastatic Pancreatic Ductal Adenocarcinoma | Phase 1 | Completed | Cantargia AB | 25 | 2021-07-19 | 2023-06-29 |
| A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors CAN04, Pembrolizumab, Carboplatin - Carcinoma, Non-Small-Cell Lung, Urothelial Carcinoma | Phase 1 | Completed | Cantargia AB | 19 | 2020-09-24 | 2023-07-14 |
| A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors CAN04, Cisplatin, Gemcitabine - Non Small Cell Lung Cancer, Pancreatic Ductal Adenocarcinoma | Phase 1 / Phase 2 | Completed | Cantargia AB | 167 | 2017-09-19 | 2024-08-22 |
Carcinoma, Non-Small-Cell Lung (2) · Triple Negative Breast Neoplasms (2) · Adenocarcinoma (1) · Adenocarcinoma of Lung (1) · Carcinoma (1) · Carcinoma, Transitional Cell (1) · Colorectal Neoplasms (1) · Lung Neoplasms (1) · Melanoma (1) · Neoplasm Metastasis (1) · Neoplasms (1) · Pancreatic Neoplasms (1) · Squamous Cell Carcinoma of Head and Neck (1)
Cantargia AB (4)
Spain (3) · Austria (1) · Belgium (1) · Denmark (1) · Estonia (1) · France (1) · Germany (1) · Latvia (1) · Lithuania (1) · Netherlands (1) · Norway (1) · Sweden (1) · United States (1)
Ignacio Garcia-Ribas, MD, PhD (2) · Ahmad Awada, Professor (1)
PMID 34903842, PMID 40310569, PMID 40680438
2017 (1)